别炫耀
发表于 2025-3-25 05:00:10
http://reply.papertrans.cn/29/2827/282679/282679_21.png
Atheroma
发表于 2025-3-25 09:29:29
Early-Phase Cancer Clinical Trials,administered to a cancer patient, so as to obtain the highest efficacy while maintaining admissible toxicity. Thus, in oncology, early-phase trials for anticancer agents are also called “dose-finding” trials. For a chemotherapeutic or cytotoxic agent, classically, the OD is determined in the phase I
gene-therapy
发表于 2025-3-25 14:26:15
http://reply.papertrans.cn/29/2827/282679/282679_23.png
ARC
发表于 2025-3-25 18:22:42
Model-Based Designs Considering Toxicity Alone, trials can be classified as rule-/algorithm- or model-based designs. In Chap. ., we focused on rule-based designs; in the present chapter, we focus on model-based designs. Model-based designs assume a certain statistical model for the monotonic dose–toxicity relationship to borrow strength across d
evasive
发表于 2025-3-25 22:40:17
http://reply.papertrans.cn/29/2827/282679/282679_25.png
Occlusion
发表于 2025-3-26 03:06:40
http://reply.papertrans.cn/29/2827/282679/282679_26.png
侵略
发表于 2025-3-26 05:00:19
http://reply.papertrans.cn/29/2827/282679/282679_27.png
–LOUS
发表于 2025-3-26 09:22:42
http://reply.papertrans.cn/29/2827/282679/282679_28.png
Ringworm
发表于 2025-3-26 15:01:09
http://reply.papertrans.cn/29/2827/282679/282679_29.png
食品室
发表于 2025-3-26 18:42:11
Mathematics and Its Applicationsmay not hold for molecularly targeted or cytostatic agents, or for immunotherapeutic agents (IAs). The ODs of such agents are found in phase I/II trials, in which both toxicity and efficacy are evaluated to determine the dose that yields the highest efficacy and admissible toxicity, or the dose that